Bleakley Financial Group LLC Sells 4,155 Shares of Ionis Pharmaceuticals, Inc. $IONS

Bleakley Financial Group LLC decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 18.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,129 shares of the company’s stock after selling 4,155 shares during the quarter. Bleakley Financial Group LLC’s holdings in Ionis Pharmaceuticals were worth $716,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its stake in shares of Ionis Pharmaceuticals by 45.6% during the 1st quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock worth $42,000 after buying an additional 433 shares during the last quarter. Ancora Advisors LLC bought a new position in Ionis Pharmaceuticals in the 1st quarter valued at about $60,000. CWM LLC raised its holdings in Ionis Pharmaceuticals by 18.7% in the 1st quarter. CWM LLC now owns 2,435 shares of the company’s stock valued at $73,000 after acquiring an additional 384 shares during the period. Parallel Advisors LLC lifted its position in Ionis Pharmaceuticals by 151.3% during the second quarter. Parallel Advisors LLC now owns 1,872 shares of the company’s stock worth $74,000 after acquiring an additional 1,127 shares during the last quarter. Finally, GF Fund Management CO. LTD. boosted its holdings in shares of Ionis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 4,042 shares of the company’s stock worth $122,000 after acquiring an additional 727 shares during the period. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ IONS opened at $70.86 on Friday. The stock has a market capitalization of $11.29 billion, a P/E ratio of -38.51 and a beta of 0.33. The stock’s fifty day moving average is $60.93 and its 200 day moving average is $44.94. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $74.42. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.51. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. The business had revenue of $452.00 million during the quarter, compared to analysts’ expectations of $270.90 million. During the same quarter in the prior year, the business posted ($0.45) earnings per share. Ionis Pharmaceuticals’s revenue was up 100.9% compared to the same quarter last year. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IONS has been the topic of a number of recent research reports. Barclays increased their target price on Ionis Pharmaceuticals from $78.00 to $82.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 23rd. Guggenheim increased their price objective on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. JPMorgan Chase & Co. raised Ionis Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $49.00 to $80.00 in a report on Wednesday, October 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Saturday. Finally, Morgan Stanley raised their price target on shares of Ionis Pharmaceuticals from $86.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $78.50.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, EVP Patrick R. O’neil sold 13,441 shares of Ionis Pharmaceuticals stock in a transaction on Monday, October 6th. The stock was sold at an average price of $69.74, for a total value of $937,375.34. Following the transaction, the executive vice president owned 53,889 shares in the company, valued at approximately $3,758,218.86. This trade represents a 19.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $71.74, for a total value of $358,700.00. Following the sale, the director owned 61,344 shares of the company’s stock, valued at approximately $4,400,818.56. This represents a 7.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 790,202 shares of company stock worth $48,538,661 in the last three months. Company insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.